Dark

AKBA
Akebia Therapeutics, Inc.
stock NASDAQ

Market Open

May 9, 2025 9:38:30 AM EDT

2.72USD+3.817%(+0.10)598,113

2.74Bid 2.75Ask 0.01Spread

Pre-market

May 9, 2025 9:22:30 AM EDT

2.60USD-0.763%(-0.02)5,608

After-hours

May 8, 2025 4:53:30 PM EDT

2.65USD+1.327%(+0.03)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 10, 2022

06:01AM EST Akebia Therapeutics to Present at H.C. Wainwright Bioconnect Conference PR Newswire

Jan 4, 2022

04:06PM EST Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule PR Newswire

08:31AM EST Akebia Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference PR Newswire

Dec 1, 2021

04:26PM EST Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule PR Newswire

Nov 24, 2021

08:36AM EST Akebia Therapeutics Announces Participation In Piper Sandler 33rd Annual Virtual Healthcare Conference Nov. 29-Dec. 2 And 4th Annual Evercore ISI HealthCONx Conference Nov. 30-Dec. 4 Benzinga

08:31AM EST Akebia Therapeutics Announces Participation in Upcoming Investor Conferences PR Newswire

Nov 15, 2021

08:31AM EST Akebia Therapeutics to Present at Jefferies London Healthcare Conference PR Newswire

Nov 11, 2021

06:47AM EST HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Raises Price Target to $10 Benzinga

Nov 4, 2021

08:27AM EDT Akebia Therapeutics Q3 EPS $(0.34) Misses $(0.32) Estimate, Sales $48.76M Miss $49.67M Estimate Benzinga

08:10AM EDT Akebia Therapeutics Q3 Net Loss $59.5 Mln Vs Net Loss $60.0 Mln Last Year RTTNews

08:05AM EDT Akebia Therapeutics Reports Third Quarter 2021 Financial Results and Highlights PR Newswire

05:00AM EDT Earnings Scheduled For November 4, 2021 Benzinga

Nov 1, 2021

04:06PM EDT Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule PR Newswire

08:10AM EDT Akebia Therapeutics Says Appoints Ron Frieson To Its Board Of Directors RTTNews

08:03AM EDT Akebia Therapeutics Appoints Ron Frieson, Healthcare Operations Leader, to PR Newswire

Oct 29, 2021

08:18AM EDT Akebia Announces Otsuka's Submission Of Initial Marketing Authorization Application To the European Medicines Agency For Vadadustat For Treatment Of Patients With Anemia Due To Chronic Kidney Disease Benzinga

08:05AM EDT Akebia Announces Otsuka's Submission Of Initial MAA To EMA For Vadadustat For Anemia Due To Chronic Kidney Disease RTTNews

08:01AM EDT Application to the European Medicines Agency for Vadadustat for the Treatment of Patients with Anemia due to Chronic Kidney Disease PR Newswire

Oct 26, 2021

08:03AM EDT Akebia Therapeutics to Report Third Quarter 2021 Financial Results and PR Newswire

Oct 25, 2021

04:46PM EDT Akebia Therapeutics Issues Statement Regarding Litigation Against Centers for Medicare & Medicaid Services and the U.S. Department of Health and Human Services Benzinga

04:40PM EDT Medicare & Medicaid Services and the U.S. Department of Health and Human Services PR Newswire

Oct 19, 2021

09:23AM EDT Akebia Therapeutics Sponsored Study Titled 'Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease' Posted To ClinicalTrials.Gov; Study Not Yet Recruiting Benzinga

Oct 18, 2021

08:19AM EDT Akebia Announces Vadadustat Efficacy And Safety Data To Be Presented At American Society Of Nephrology Kidney Week 2021 Benzinga

08:14AM EDT Akebia Says Vadadustat Efficacy And Safety Data To Be Presented At American Society Of Nephrology Kidney Week 2021 RTTNews

08:01AM EDT Akebia Announces Vadadustat Efficacy and Safety Data to be Presented at PR Newswire

Oct 1, 2021

04:06PM EDT Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule PR Newswire

Sep 1, 2021

08:03AM EDT Akebia Therapeutics Announces September 2021 Investor Conference Schedule PR Newswire

Aug 5, 2021

08:13AM EDT Akebia Therapeutics Q2 EPS $(0.51) Misses $(0.32) Estimate, Sales $52.91M Beat $52.88M Estimate Benzinga

08:01AM EDT Akebia Therapeutics Q2 Net Loss $83 Mln Vs $175.8 Mln Last Year RTTNews

07:59AM EDT Akebia Therapeutics Reports Second Quarter 2021 Financial Results and PR Newswire

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

Aug 3, 2021

04:06PM EDT Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule PR Newswire

Jul 26, 2021

08:01AM EDT Akebia Therapeutics to Report Second Quarter 2021 Financial Results and Discuss PR Newswire

Jul 14, 2021

12:30PM EDT Akebia Shares Up 5% For Session; Recently Seeing Block Trade Of 1.6M Shares At $3.50/Share Benzinga

Jul 1, 2021

04:05PM EDT Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule PR Newswire

Jun 21, 2021

09:43AM EDT Akebia Therapeutics Insights: Return On Capital Employed Benzinga

Jun 10, 2021

12:43PM EDT Akebia Therapeutics Posts Study Titled 'Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants (IMPACT)' To ClinicalTrials.Gov Benzinga

Jun 8, 2021

08:51AM EDT Cramer Gives His Opinion On Novavax, Exact Sciences And More Benzinga

Jun 4, 2021

10:27AM EDT Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise Benzinga

08:08AM EDT Cyclerion Enters Exclusive, Global License Agreement With Akebia Therapeutics For Praliciguat RTTNews

Jun 3, 2021

08:16AM EDT Akebia Therapeutics Presents Data From Phase 3 Program For Vadadustat At European Renal Association RTTNews

08:02AM EDT Akebia Therapeutics Announces Presentations at ERA-EDTA Virtual Congress 2021 PR Newswire

Jun 2, 2021

04:06PM EDT Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule PR Newswire

Jun 1, 2021

03:23PM EDT Looking Into Akebia Therapeutics's Return On Capital Employed Benzinga

11:44AM EDT Akebia Therapeutics shares were trading higher after the company, and Otsuka, announced FDA acceptance for filing of the New Drug Application for Vadadustat. Benzinga

08:58AM EDT Akebia Therapeutics Stock Jumps as FDA Accepts Vadadustat US Application in CKD-Related Anemia Benzinga

06:03AM EDT Akebia, Otsuka: FDA Accepts NDA Filing For Vadadustat ForAnemia Due To CKD In Patients On Dialysis & Not On Dialysis RTTNews

06:01AM EDT for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis PR Newswire

06:01AM EDT Akebia And Otsuka Announce FDA Acceptance For Filing Of New Drug Application For Vadadustat Benzinga

May 10, 2021

08:39AM EDT Akebia Therapeutics Q1 Net Loss $69.6 Mln Vs. Net Loss $60.7 Mln Last Year RTTNews

08:24AM EDT Recap: Akebia Therapeutics Q1 Earnings Benzinga

08:11AM EDT Akebia Therapeutics Q1 EPS $(0.45) Misses $(0.36) Estimate, Sales $52.30M Beat $42.84M Estimate Benzinga

08:01AM EDT Akebia Reports First Quarter 2021 Financial Results and Highlights Recent PR Newswire

04:09AM EDT Earnings Scheduled For May 10, 2021 Benzinga

May 4, 2021

04:06PM EDT Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule PR Newswire

Apr 29, 2021

08:15AM EDT The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx Benzinga

Apr 28, 2021

05:20PM EDT Program of Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease PR Newswire

08:01AM EDT Akebia Therapeutics to Report First Quarter 2021 Financial Results and Discuss PR Newswire

Apr 12, 2021

08:01AM EDT Akebia Therapeutics to Present at 20th Annual Needham Virtual Healthcare PR Newswire

Apr 2, 2021

04:05PM EDT Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule PR Newswire

Mar 30, 2021

06:03AM EDT Akebia Submits New Drug Application To FDA For Vadadustat For Treatment Of Anemia Due To Chronic Kidney Disease In Adult Patients On Dialysis And Not On Dialysis Benzinga

06:02AM EDT Akebia Submits NDA To FDA For Vadadustat RTTNews

06:01AM EDT Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis PR Newswire

Mar 25, 2021

08:06AM EDT Akebia Therapeutics Announces Poster Presentations And Educational Symposium At National Kidney Foundation 2021 Virtual Spring Clinical Meeting Apr. 6-10 Benzinga

08:02AM EDT Akebia Therapeutics Announces Poster Presentations and Educational Symposium at PR Newswire

Mar 24, 2021

08:10AM EDT Akebia Reports Approval For Addl Indication Of Riona For Treatment Of Iron Deficiency Anemia In Adult Patients In Japan RTTNews

08:06AM EDT Akebia Therapeutics Announces Approval For Additional Indication Of Riona For The Treatment Of Iron Deficiency Anemia In Adult Patients In Japan Benzinga

08:02AM EDT (ferric citrate hydrate) for the Treatment of Iron Deficiency Anemia in Adult Patients in Japan PR Newswire

Mar 11, 2021

08:02AM EST Akebia Therapeutics Celebrates World Kidney Day and National Kidney Month PR Newswire

Mar 8, 2021

10:04AM EST Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2021 Benzinga

09:31AM EST Cantor Fitzgerald Initiates Coverage On Akebia Therapeutics with Overweight Rating, Announces Price Target of $8 Benzinga

07:21AM EST 10 Biggest Price Target Changes For Monday Benzinga

06:21AM EST HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Lowers Price Target to $6 Benzinga

Mar 2, 2021

04:06PM EST Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule PR Newswire

10:42AM EST Looking Into Akebia Therapeutics's Return On Capital Employed Benzinga

08:01AM EST Akebia Therapeutics to Present at H.C. Wainwright Global Life Sciences PR Newswire

Feb 25, 2021

08:46AM EST Akebia Q4 Total Revenue $56.7 Mln Vs. $69.6 Mln Prior Year RTTNews

08:46AM EST Akebia Therapeutics Q4 EPS $(0.60) Misses $(0.40) Estimate, Sales $56.70M Beat $51.16M Estimate Benzinga

08:08AM EST The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants Benzinga

08:02AM EST Akebia Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides PR Newswire

04:03AM EST Earnings Scheduled For February 25, 2021 Benzinga

Feb 18, 2021

08:01AM EST Akebia Therapeutics Appoints LeAnne M. Zumwalt, Dialysis Industry Leader, to PR Newswire

Feb 8, 2021

08:01AM EST Akebia Therapeutics to Report Fourth Quarter and Full-Year 2020 Financial PR Newswire

Feb 2, 2021

04:05PM EST Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule PR Newswire

Jan 29, 2021

10:33AM EST Return On Capital Employed Overview: Akebia Therapeutics Benzinga

10:04AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 29, 2021 Benzinga

08:18AM EST JP Morgan Downgrades Akebia Therapeutics to Underweight Benzinga

Jan 6, 2021

08:01AM EST Akebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 Conference PR Newswire

Jan 5, 2021

04:07PM EST Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Benzinga

04:06PM EST Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule PR Newswire

Jan 4, 2021

08:02AM EST Akebia Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference PR Newswire

Dec 9, 2020

08:01AM EST AkebiaShares Program: Current Approaches for Managing Hyperphosphatemia and PR Newswire

Dec 2, 2020

04:05PM EST Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule PR Newswire

Nov 24, 2020

08:01AM EST Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual PR Newswire

Nov 19, 2020

05:53AM EST What's moving these stocks in the pre-market hours today? RTTNews

Nov 18, 2020

09:37AM EST Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on PR Newswire

Nov 17, 2020

12:00PM EST Q3 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios Benzinga

Nov 16, 2020

08:31AM EST Akebia Announces Manuscript Highlighting Global Phase 3 INNO2VATE Program Rationale, Study Design, Baseline Characteristics Published In Peer-Reviewed Medical Journal Benzinga

08:31AM EST Rationale, Study Design and Baseline Characteristics Published in Peer-Reviewed Medical Journal PR Newswire

Nov 5, 2020

08:26AM EST Akebia Q3 Loss/Shr $0.42 Vs Loss $0.46 Lat Year RTTNews

08:09AM EST Akebia Therapeutics Q3 EPS $(0.42) Misses $(0.17) Estimate, Sales $60.00M Miss $84.90M Estimate Benzinga

08:04AM EST Akebia Reports Third Quarter 2020 Financial Results and Recent Business Updates PR Newswire

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 4, 2020

06:16PM EST Notable Earnings Watchlist For Thursday, Nov. 5, 2020 Before Market Open: MUR, ODP, WRK, REGN, ZTS, BLL, CAH, CIR, CBB, ABC, AGIO, AKBA, CMLS, AZN, HBI, CPRI, CNP, CNHI, CRON, GM, HII, NYT, PPL, MLCO, TEVA, BMY, BABA, AAWW, DUK, AMRN, CI, BDX Benzinga

Nov 3, 2020

04:06PM EST Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule PR Newswire

Nov 2, 2020

08:59AM EST Morgan Stanley Maintains Equal-Weight on Rocket Companies, Lowers Price Target to $23 Benzinga

Oct 30, 2020

08:55AM EDT Stocks Trading Near 52-Week Lows Before Open On Friday, Oct. 30, 2020: TUR, HPR, WBA, CATO, ASAN, SUMO, PSHG, IPOC, AKBA, CATB, INTC, DBVT Benzinga

08:09AM EDT The Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinson's Study, 2 Biotechs Make Wall Street Debuts Benzinga

Oct 29, 2020

07:30AM EDT The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal Benzinga

Oct 26, 2020

08:01AM EDT Akebia Therapeutics to Report Third Quarter 2020 Financial Results and Discuss PR Newswire

07:08AM EDT HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Lowers Price Target to $9 Benzinga

Oct 23, 2020

11:16AM EDT Akebia Therapeutics Reports Results From PRO2TECT Phase 3 Program Of Vadaustat For Treatment Of Anemia: Data Shows No Clinically Meaningful Increase In Risk Of MACE Benzinga

11:15AM EDT for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients Not on Dialysis During Late-Breaking Session at American Society of Nephrology Kidney Week 2020 Reimagined PR Newswire

11:07AM EDT Akebia Therapeutics Shares Halted On News Pending Benzinga

Oct 22, 2020

05:08PM EDT Akebia Announces Presentation Of Clinical Data From Its Global INNO2VATE Phase 3 Program RTTNews

05:06PM EDT Efficacy and Cardiovascular Safety of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis PR Newswire

Oct 9, 2020

04:50PM EDT Akebia to Present Global Phase 3 Vadadustat Data at American Society of PR Newswire

Oct 2, 2020

04:05PM EDT Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule PR Newswire

Sep 8, 2020

08:02AM EDT Akebia Therapeutics Announces September 2020 Investor Conference Schedule PR Newswire

Sep 4, 2020

08:35AM EDT Morgan Stanley Maintains Equal-Weight on Akebia Therapeutics, Lowers Price Target to $3 Benzinga

08:16AM EDT 10 Biggest Price Target Changes For Friday Benzinga

08:09AM EDT BTIG Maintains Buy on Akebia Therapeutics, Lowers Price Target to $6 Benzinga

06:20AM EDT HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Lowers Price Target to $10 Benzinga

Sep 3, 2020

02:31PM EDT Mid-Afternoon Market Update: Nasdaq Tumbles 575 Points; PagerDuty Shares Tumble On Weak Outlook Benzinga

12:13PM EDT Mid-Day Market Update: Dow Tumbles Over 500 Points; Fulgent Genetics Shares Jump Benzinga

10:18AM EDT Mid-Morning Market Update: Markets Open Lower; Campbell Soup Beats Q4 Views Benzinga

09:53AM EDT ROCE Insights For Akebia Therapeutics Benzinga

08:00AM EDT Benzinga Pro's Top 5 Stocks To Watch For Thursday, Sept. 3, 2020: DKNG, AKBA, CORT, NNVC, SWBI Benzinga

07:48AM EDT Akebia: Vadadustat Trial Achieves Efficacy Endpoints; RTTNews

07:26AM EDT Akebia Therapeutics Shares To Resume Trade At 7:30 a.m. EDT Benzinga

07:20AM EDT Akebia: PRO2TECT Achieves Primary, Key Secondary Efficacy Endpoints; Does Not Meet Primary Safety MACE Endpoint RTTNews

07:07AM EDT Akebia Therapeutics Says 'Company believes totality of data from global Phase 3 program (PRO2TECT and INNO2VATE) supports NDA submission for both non-dialysis and dialysis indications' Benzinga

07:07AM EDT Akebia Therapeutics Announces Top-Line Results From PRO2TECT Global Phase 3 Program Of Vadadustat; Achieved Primary And Key Secondary Efficacy Endpoint, Did Not Meet Primary Safety MACE Endpoint Benzinga

07:01AM EDT Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients Not on Dialysis PR Newswire

Sep 2, 2020

04:05PM EDT Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule PR Newswire

Aug 26, 2020

08:10AM EDT Akebia Therapeutics Announces Commercial Launch Of VAFSEO Oral Treatment For Anemia Due To Chronic Kidney Disease, In Japan Benzinga

08:06AM EDT Akebia Therapeutics Announces First Commercial Launch Of VAFSEO In Japan RTTNews

08:02AM EDT tablets), a New Oral Treatment for Anemia Due to Chronic Kidney Disease, in Japan PR Newswire

Aug 10, 2020

04:20PM EDT Akebia Therapeutics Q2 EPS $(0.44) Beats $(0.50) Estimate, Sales $90.14M Beat $74.18M Estimate Benzinga

04:01PM EDT Akebia Reports Second Quarter 2020 Financial Results PR Newswire

04:10AM EDT Earnings Scheduled For August 10, 2020 Benzinga

Aug 4, 2020

04:06PM EDT Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule PR Newswire

Aug 3, 2020

08:01AM EDT Akebia Therapeutics to Report Second Quarter 2020 Financial Results PR Newswire

Jul 15, 2020

09:23AM EDT Morgan Stanley Maintains Equal-Weight on Akebia Therapeutics, Raises Price Target to $12 Benzinga

Jul 14, 2020

08:02AM EDT Akebia Announces Initiation Of Investigator-Sponsored Study Evaluating Vadadustat For Prevention And Treatment Of ARDS In Patients Hospitalized With COVID-19 Benzinga

08:02AM EDT Vadadustat for Prevention and Treatment of ARDS in Patients Hospitalized with COVID-19 PR Newswire